KR880009649A - 과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료에서의 피리독신 유도체의 사용 - Google Patents

과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료에서의 피리독신 유도체의 사용 Download PDF

Info

Publication number
KR880009649A
KR880009649A KR1019880001692A KR880001692A KR880009649A KR 880009649 A KR880009649 A KR 880009649A KR 1019880001692 A KR1019880001692 A KR 1019880001692A KR 880001692 A KR880001692 A KR 880001692A KR 880009649 A KR880009649 A KR 880009649A
Authority
KR
South Korea
Prior art keywords
pyridoxine
atherosclerosis
treatment
derivatives
hyperlipidemia
Prior art date
Application number
KR1019880001692A
Other languages
English (en)
Other versions
KR950009094B1 (ko
Inventor
스페크 울리히
Original Assignee
스페크 울리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스페크 울리히 filed Critical 스페크 울리히
Publication of KR880009649A publication Critical patent/KR880009649A/ko
Application granted granted Critical
Publication of KR950009094B1 publication Critical patent/KR950009094B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

내용 없음.

Description

과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료에서의 피리독신 유도체의 사용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. DE 24 61 742 C2에 따른 피리독신-5-'-인산에스테르글루타민산염 및 아스파라긴산염을 제외한 피리독신 유도체와 이들의 염의 과유지질혈증 및 아테롬성 동맥경화증의 예방 및 치료용 용도.
  2. 제1항에 있어서, 피리독살 및/또는 피리독살인산염 및/또는 피리독사민 및/또는 피리독사민인산염을 사용하는 것을 특징으로 하는 피리독신 유도체의 용도.
  3. 제1항에 있어서, 생리학적으로 흠잡을데 없는 제약학적 부형제와 보조제를 피리독신 유도체 또는 여러 유도체에 첨가하는 것을 특징으로 하는 피리독신 유도체의 용도.
  4. 제1항 내지 제3항에 있어서, 피리독신 유도체를 과유지질혈증과 아테롬성 동맥경화증 또는 부수되는 질병을 치료하는데 다른 활성성분과 똑같이 병용으로 사용하는 것을 특징으로 하는 피리독신 유도체의 용도.
  5. DE 24 61 742 C2 에 따른 피리독신-5'-인산에스테르 글루타민산염 및 아스파라긴산염을 제외한 피리독신 유도체 또는 이들의 염의 과유지질혈증 및 아테롬성 동맥경화증의 예방 및 치료용 용도.
  6. 피리독살 및/또는 피리독살 인산염 및/또는 피리독사민 및/또는 피리독사민인산염 또는 이들의 염의 과유지질혈증 및 아테롬성 동맥경화증의 예방 및 치료용 약제 제조용 용도.
  7. 제5항에 있어서, 피리독신 유도체를 제약학적으로 안전한 부형제 및/또는 보조제와 함께 고체형태 또는 수용액으로서 제조하는 것을 특징으로 하는 피리독신 유도체의 용도.
  8. 제1항에 있어서, 구강 사용을 위하여 생리학적으로 흠잡을데 없는 제약학적 담체 및 보조제로서 제조하는 것을 특징으로 하는 피리독신 유도체의 용도.
  9. 제1항 내지 제7항에 있어서, 위장 쥬스에 저항하는 형태로된 생리학적으로 흠잡을데 없는 제약학적 담체와 보조제로 제조하는 것을 특징으로 하는 피리독신 유도체의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880001692A 1987-02-18 1988-02-17 과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료용 피리독신 유도체를 함유한 제약학적 조성물 KR950009094B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3705549.6 1987-02-18
DE19873705549 DE3705549A1 (de) 1987-02-18 1987-02-18 Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose

Publications (2)

Publication Number Publication Date
KR880009649A true KR880009649A (ko) 1988-10-04
KR950009094B1 KR950009094B1 (ko) 1995-08-14

Family

ID=6321453

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880001692A KR950009094B1 (ko) 1987-02-18 1988-02-17 과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료용 피리독신 유도체를 함유한 제약학적 조성물

Country Status (12)

Country Link
EP (1) EP0282696B1 (ko)
JP (2) JPH0710777B2 (ko)
KR (1) KR950009094B1 (ko)
AT (1) ATE82125T1 (ko)
CA (1) CA1340246C (ko)
DE (2) DE3705549A1 (ko)
DK (1) DK55888A (ko)
EG (1) EG18335A (ko)
ES (1) ES2052609T3 (ko)
GR (1) GR3006693T3 (ko)
HU (1) HUT47850A (ko)
ZA (1) ZA88577B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
AU1444600A (en) * 1998-10-09 2000-05-01 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
AU763464B2 (en) 1999-03-08 2003-07-24 Medicure Inc. Pyridoxal analogues for vitamin B-6 disorders
CA2376029A1 (en) 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
AU2001237185B2 (en) 2000-02-29 2006-02-02 Medicure International Inc. Cardioprotective phosphonates and malonates
CA2404329A1 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
JP2004502757A (ja) 2000-07-07 2004-01-29 メディキュア　インターナショナル　インコーポレイテッド ピリドキシンおよびピリドキサール類縁体：心血管系治療薬
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
WO2004084895A2 (en) * 2003-03-27 2004-10-07 Medicure, Inc. Modulation of cell death
EP1817288A4 (en) 2004-10-28 2009-08-26 Medicure Int Inc DUAL ANTIPLÄTTCHEN / ANTIKOAGULANS PYRIDOXINANALOGE
CA2593793A1 (en) * 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
FR3038227B1 (fr) 2015-06-30 2018-08-17 Assistance Publique - Hopitaux De Paris Formulation effervescente a base de pyridoxal-5-phosphate
WO2020003363A1 (ja) * 2018-06-25 2020-01-02 学校法人近畿大学 ニコチン摂取の影響による血管の劣化を防止するための健康食品または医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3373E (fr) 1904-02-26 1904-10-27 Joseph Louis Felix Garrigou Procédé de traitement des vidanges et déchets organiques, et appareil d'ensemble permettant sa mise en oeuvre
FR6707M (ko) * 1966-04-29 1969-02-17
GB1070120A (en) * 1966-05-06 1967-05-24 Tanabe Seiyaku Co Pyridoxine derivative and the preparation thereof
FR7238M (ko) * 1968-03-27 1969-09-01
FR2035765A1 (en) 1969-03-06 1970-12-24 Inst Rech Scient Medicaments contg pyridoxine heparinates or - other vitamin b6 heparinates
JPS5347110B2 (ko) * 1971-11-02 1978-12-19
FR2176509A2 (en) 1972-03-21 1973-11-02 Inst Rech Scient Pyridoxine p-chlorophenoxyisobutyrate prodn - giving very pure product from corresp acid and pyridoxine
JPS5018470A (ko) * 1973-05-31 1975-02-26
FR2260330A1 (en) 1974-02-07 1975-09-05 Innothera Lab Sa Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index
CH607773A5 (en) 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
DE2461742C2 (de) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2349330A1 (fr) * 1976-04-29 1977-11-25 Savini Emile Composition destinee au traitement des hyperlipidemies
JPS5347110A (en) * 1976-10-12 1978-04-27 Osaka Bosui Kensetsusha Kk Impermeable wall forming method

Also Published As

Publication number Publication date
EP0282696A3 (en) 1989-06-14
JP2588686B2 (ja) 1997-03-05
KR950009094B1 (ko) 1995-08-14
DK55888D0 (da) 1988-02-03
GR3006693T3 (ko) 1993-06-30
ES2052609T3 (es) 1994-07-16
ZA88577B (en) 1988-07-28
EP0282696A2 (de) 1988-09-21
HUT47850A (en) 1989-04-28
EG18335A (en) 1992-09-30
JPS63203621A (ja) 1988-08-23
DE3875760D1 (de) 1992-12-17
JPH0710777B2 (ja) 1995-02-08
JPH07238020A (ja) 1995-09-12
DE3705549A1 (de) 1988-09-01
EP0282696B1 (de) 1992-11-11
DK55888A (da) 1988-08-19
CA1340246C (en) 1998-12-15
ATE82125T1 (de) 1992-11-15

Similar Documents

Publication Publication Date Title
KR880009649A (ko) 과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료에서의 피리독신 유도체의 사용
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
SE9002500D0 (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
KR970025615A (ko) 암 전이 억제제
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
EP0369887A3 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
ATE82120T1 (de) Kalziumzusaetze.
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
NO933321L (no) NADH og NADPH som legemiddel til behandling av Mobus Alzheimer
DE59509928D1 (de) Antihyperglykämisch wirksame Arzneimittel
ATE159427T1 (de) Anwendung des n-n-butyl-derivates von desoxynojirimycin zur herstellung eines arzneimittels zur inhibierung von hiv-virus
LV10051A (lv) Liofilizeta ifosfamida iegusanas veids
EP0471388A3 (de) Mittel zur Behandlung der Herzinsuffizienz
NO164958C (no) Fremgangsmaate for fremstilling av dipyridamol-preparater med ph-uavhengig, regulert frigjoering.
ATE66150T1 (de) Pharmazeutische zubereitung fuer orale verabreichung von eisensalzen, verwendbar zur behandlung von anaemien durch eisenmangel.
ES512748A0 (es) "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina".

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990617

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee